• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

    251.58 -1.28 (-0.51%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,493,344
    Open 255.22
    Bid (Size) 256.00 (100)
    Ask (Size) 261.00 (100)
    Prev. Close 252.86
    Today's Range 248.45 - 255.22
    52wk Range 105.00 - 261.30
    Shares Outstanding 62,311,104
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Jazz Pharmaceuticals Q2 Earnings Call Highlights ↗
    Jazz Pharmaceuticals (NASDAQ:JAZZ) reported second-quarter 2026 revenue of $1.21 billion, up 16% from a year earlier, as growth across its sleep, epilepsy and oncology portfolios drove record quarterly... 
    Via MarketBeat
    Topics Cannabis Earnings
    News headline image
    Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales
    Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 15.5% year on year t... 
    Via StockStory

    Performance

    YTD
    +45.3%
    +45.3%
    1 Month
    +3.0%
    +3.0%
    3 Month
    +20.9%
    +20.9%
    6 Month
    +50.4%
    +50.4%
    1 Year
    +116.7%
    +116.7%

    More News

    Read More
    News headline image
    Jazz Pharmaceuticals (JAZZ) Q2 Earnings: What To Expect
    Via StockStory
    Topics Artificial Intelligence
    Cannabis Theme's Hidden Strength: Established Players Outshining Pure Plays ↗
    Via Chartmill
    Topics Cannabis
    Cannabis Theme Rally Powered by Profitability, Not Pure-Play Speculation ↗
    Via Chartmill
    Topics Cannabis
    Cannabis Stocks Split into Two Camps: Profitable Operators vs. High-Growth Speculation ↗
    Via Chartmill
    Topics Cannabis
    JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Presents a Decent Value Opportunity with Strong Valuation and Growth Potential ↗
    Via Chartmill
    Jazz Pharmaceuticals (NASDAQ:JAZZ) Flashes Perfect Minervini Trend Template Score with 116% Annual Surge ↗
    Via Chartmill
    News headline image
    3 Value Stocks with Open Questions
    Via StockStory
    News headline image
    3 Overrated Stocks Walking a Fine Line
    Via StockStory
    News headline image
    Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks ↗
    Via The Motley Fool
    News headline image
    Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
    From AbCellera Biologics Inc.
    Via Business Wire
    Jazz Pharmaceuticals (NASDAQ:JAZZ) Surges 3.7% After-Hours on Q1 2026 Revenue and EPS Beat ↗
    Via Chartmill
    News headline image
    Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?
    Via StockStory
    Topics Stocks
    News headline image
    Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ)
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    3 Unpopular Stocks We Find Risky
    Via StockStory
    Topics Credit Cards
    News headline image
    What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    3 Healthcare Stocks We Think Twice About
    Via StockStory
    News headline image
    3 Mid-Cap Stocks We’re Skeptical Of
    Via StockStory
    News headline image
    Is Marriott Stock a Buy After GMT Capital Initiated a Position Worth Over $66 Million? ↗
    Via The Motley Fool
    News headline image
    Jazz Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions
    Via StockStory
    Topics Earnings
    News headline image
    Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
    Via StockStory
    News headline image
    JAZZ Q1 Deep Dive: Oncology and Neuroscience Drive Double-Digit Revenue Growth, Eyes on Upcoming Approvals
    Via StockStory
    News headline image
    Jazz (JAZZ) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 Sales
    Via StockStory

    Frequently Asked Questions

    Is Jazz Pharmaceuticals plc - Ordinary Shares publicly traded?
    Yes, Jazz Pharmaceuticals plc - Ordinary Shares is publicly traded.
    What exchange does Jazz Pharmaceuticals plc - Ordinary Shares trade on?
    Jazz Pharmaceuticals plc - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Jazz Pharmaceuticals plc - Ordinary Shares?
    The ticker symbol for Jazz Pharmaceuticals plc - Ordinary Shares is JAZZ on the Nasdaq Stock Market
    What is the current price of Jazz Pharmaceuticals plc - Ordinary Shares?
    The current price of Jazz Pharmaceuticals plc - Ordinary Shares is 251.58
    When was Jazz Pharmaceuticals plc - Ordinary Shares last traded?
    The last trade of Jazz Pharmaceuticals plc - Ordinary Shares was at 08/03/26 04:00 PM ET
    What is the market capitalization of Jazz Pharmaceuticals plc - Ordinary Shares?
    The market capitalization of Jazz Pharmaceuticals plc - Ordinary Shares is 15.68B
    How many shares of Jazz Pharmaceuticals plc - Ordinary Shares are outstanding?
    Jazz Pharmaceuticals plc - Ordinary Shares has 16B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.